PMID- 32804557
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 48
IP  - 8
DP  - 2020 Aug
TI  - Survival analysis of afatinib versus erlotinib for individuals with advanced 
      del19 lung adenocarcinoma with asymptomatic brain metastasis after 
      pemetrexed-cisplatin chemotherapy: a retrospective study.
PG  - 300060520937093
LID - 10.1177/0300060520937093 [doi]
LID - 0300060520937093
AB  - OBJECTIVE: To evaluate survival following afatinib (AF) and erlotinib (ER) 
      treatment in advanced del19 lung adenocarcinoma (AD19LA) with asymptomatic brain 
      metastasis (ABM) after pemetrexed-cisplatin chemotherapy (PCC). METHODS: Data 
      were retrospectively analysed from individuals with AD19LA and ABM after PCC who 
      received AF or ER for 2 years or until intolerable adverse events (AEs), 
      withdrawal, or death. The primary outcome was survival; secondary outcomes were 
      AEs. RESULTS: The final analysis included 174 AD19LA individuals (AF: n = 86; ER: 
      n = 88) with a median follow-up of 24.2 months (IQR 2.1-28.3). Significant 
      differences in overall survival (16.2 months [95%CI 15.4-17.1] for AF vs 7.2 
      months [95%CI 6.3-8.1] for ER) (HR 0.50, 95%CI 0.36-0.71, p<0.0001) and median 
      progression-free survival (9.4 months [95%CI 8.5-9.7] for AF vs 5.6 months 
      [4.7-6.2] for ER) (HR 0.66, 95%CI 0.47-0.94, p=0.02) were observed between the 
      groups. Rates of all-grade AEs were 82.5% for AF and 72.7% for ER, and rates of 
      grade >/=3 AEs were 37.2% for AF and 34.0% for ER. CONCLUSION: Compared with ER, AF 
      treatment may be more beneficial in terms of survival in the management of AD19LA 
      after PCC with a tolerable safety profile.
FAU - Jiang, Ye
AU  - Jiang Y
AD  - Department of Neurology, Affiliated Hospital of Hebei University, Baoding, Hebei, 
      China.
FAU - Chen, Wenli
AU  - Chen W
AD  - Department of Neurosurgery, The First Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Yu, Weiguang
AU  - Yu W
AUID- ORCID: 0000-0001-6190-8336
AD  - Department of Orthopedics, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Shi, Ning
AU  - Shi N
AD  - Department of Nuclear medicine, Affiliated Hospital of Hebei University, Baoding, 
      Hebei, China.
FAU - Han, Guowei
AU  - Han G
AUID- ORCID: 0000-0002-3288-1717
AD  - Department of Orthopedics, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - Mao, Shuai
AU  - Mao S
AD  - Department of Cardiology, Nanjing Brain Hospital Affiliated to Nanjing Medical 
      University, Nanjing, China.
FAU - Zhang, Xinlei
AU  - Zhang X
AD  - Department of Cardiology, Nanjing Brain Hospital Affiliated to Nanjing Medical 
      University, Nanjing, China.
FAU - Chen, Meiji
AU  - Chen M
AD  - Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Quinazolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 41UD74L59M (Afatinib)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - *Adenocarcinoma of Lung/drug therapy
MH  - Afatinib/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Brain Neoplasms/drug therapy
MH  - Cisplatin/therapeutic use
MH  - Disease-Free Survival
MH  - ErbB Receptors/genetics
MH  - Erlotinib Hydrochloride/therapeutic use
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Mutation
MH  - Pemetrexed/therapeutic use
MH  - Quinazolines/adverse effects
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC7432978
OTO - NOTNLM
OT  - Afatinib
OT  - adverse event
OT  - asymptomatic brain metastasis
OT  - chemotherapy
OT  - erlotinib
OT  - lung adenocarcinoma
OT  - survival
EDAT- 2020/08/18 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/08/17
CRDT- 2020/08/18 06:00
PHST- 2020/08/18 06:00 [entrez]
PHST- 2020/08/18 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/08/17 00:00 [pmc-release]
AID - 10.1177_0300060520937093 [pii]
AID - 10.1177/0300060520937093 [doi]
PST - ppublish
SO  - J Int Med Res. 2020 Aug;48(8):300060520937093. doi: 10.1177/0300060520937093.